Cantor Fitzgerald Reiterates a Buy Rating on HCA Healthcare (HCA) With a $444 PT

HCA Healthcare, Inc. (NYSE:HCA) is one of the best medical stocks to buy now. In a report released on September 26, Sarah James from Cantor Fitzgerald reiterated a Buy rating on HCA Healthcare, Inc. (NYSE:HCA) and set a price target of $444.00.

HCA Healthcare, Inc. (NYSE:HCA) reported a 6.4% growth in its revenues for fiscal Q2 2025 to $18.605 billion, while net income attributable to the company rose 13.1% to $1.653 billion.

Management further reported that diluted EPS rose 23.5% to $6.83 per diluted share, while diluted EPS, as adjusted, grew 24.4% to $6.84 per diluted share. Adjusted EBITDA also rose 8.4% to $3.849 billion.

HCA Healthcare, Inc. (NYSE:HCA) is a health care services company involved in the operation of hospitals, urgent care facilities, freestanding surgery centers and emergency care facilities, diagnostic and imaging centers, walk-in clinics, radiation and oncology therapy centers, and more.

While we acknowledge the potential of HCA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.